Harrow: The Q2 Turnaround Is Enough For A Cautious Buy

Impact · against what's priced in

Harrow receives a positive catalyst as record demand for IHEEZO and improved economics for VEVYE provide tangible evidence of operational leverage. The analyst upgrade to a 'cautious Buy' with a $52 price target suggests the market has not yet fully priced in the company's current execution trajectory.

HROW+0.60

No priced-in read yet

In context

Record demand for IHEEZO despite reimbursement headwinds and improved economics for VEVYE validate the growth thesis and operational leverage.

Read from the article alone

• revenue growth
• healthcare
• HROW
• analyst upgrade
• operating leverage
• pharma
• price target

Search tags